Dimitrios Vavilis

Dr. Dimitrios Vavilis


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
MLMaria Lantzanaki
Maria Lantzanaki
TVTheofanis Vavilis
Theofanis Vavilis
VHVikentia Harizopoulou
Vikentia Harizopoulou
HBHelen Bili
Helen Bili
Dimitrios G. GoulisDimitrios G. Goulis
Dimitrios G. Goulis
DVDimitrios Vavilis
Dimitrios Vavilis
Ceramides are a group of sphingolipids located in the external plasma membrane layer and act as messengers in cellular pathways such as inflammatory processes and apoptosis. Plasma ceramides are biomarkers of cardiovascular disease, type 2 diabetes mellitus, Alzheimer’s disease, various autoimmune conditions and cancer. During pregnancy, ceramides play an important role as stress mediators, especially during implantation, delivery and lactation. Based on the current literature, plasma ceramides could be potential biomarkers of obstetrical adverse outcomes, although their role in metabolic pathways under such conditions remains unclear. This review aims to present current studies that examine the role of ceramides during pregnancy and obstetrical adverse outcomes, such as pre-eclampsia, gestational diabetes mellitus and other complications.

16 November 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
MLMaria Lantzanaki
Maria Lantzanaki
ΣΒΣταυρούλα Βενέτη
Σταυρούλα Βενέτη
GMGesthimani Mintziori
Gesthimani Mintziori
Olga BegouOlga Begou
Olga Begou
PPPanagiotis D. Pappas
Panagiotis D. Pappas
DVDimitrios Vavilis
Dimitrios Vavilis
Ceramides, a sphingolipid group that acts as a messenger in cellular differentiation, proliferation, apoptosis and senescence, have been associated with cardiovascular disease and type 2 diabetes. The evidence for an association between ceramides and gestational diabetes mellitus (GDM) is scarce. This case-control study aimed to compare women with GDM with healthy, pregnant women in terms of plasma ceramide concentrations at the time of delivery. Ninety-two pregnant women were included in this case-control study, 29 in the GDM group and 63 in the control group. All women were admitted to a tertiary academic hospital for a full-term delivery. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was applied for the quantification of four molecular ceramides, namely Cer d18:1/16:0 (Cer16:0), Cer d18:1/18:0 (Cer18:0), Cer d18:1/24:0 (Cer24:0) and Cer d18:1/24:1 (Cer24:1) in plasma samples. The raw chromatographic data obtained from the LC-MS/MS analysis were processed using Analyst SCIEX (AB Sciex Pte. Ltd., USA). In a univariate statistical analysis, Cer24:0 concentration was significantly lower in the GDM group compared with the control group (p = 0.01). The present study demonstrated lower Cer24:0 concentrations in pregnancies complicated by GDM. Further prospective studies are required to enhance the results of this study.